MGAT5 and neoplasm: To this end, we subcutaneously implanted Mgat5-KO and control wild-type (WT) tumor cells into Batf3–/– hosts, which lack conventional type 1 DCs (cDC1s) that are specialized for CD8+ T cell activation and cross-presentation (43).